2004 Cannabinoids Clinical Trials 
Otherside Farms
JANUARY 23, 2019
Differential effects of repeated low dose treatment with the cannabinoid agonist WIN 55,212-2 in experimental models of bone cancer pain and neuropathic pain. Reduction of bone cancer pain by activation of spinal cannabinoid receptor 1 and its expression in the superficial dorsal horn of the spinal cord in a murine model of bone cancer pain.
Cannabis Law Report
JULY 12, 2019
International Cannabinoid Cancer Research Institute (Draft 5). This paper seeks to answer why refined cannabinoids have more side effects than the natural cannabis product, as well as the possible etiology of said adverse reactions. Also discussed are other attempts at affecting the cannabinoid system from a singular standpoint.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Greencamp
AUGUST 16, 2018
Exploring the available research on ALS and cannabinoids. The CBD cannabinoid is proven to be an exceptional seizure-controlling agent for epilepsy patients, and also shows great promise for treating Parkinson’s , Alzheimer’s and Multiple Sclerosis. The first study I will reference is from 2006, conducted on mice.
Greencamp
FEBRUARY 17, 2019
We produce endocannabinoids—internal cannabinoid-like compounds, that bind to these cellular endocannabinoid receptors. Cannabinoids: A Guide to 13 Bioactive Compounds from Weed. Cannabis research still has a long way to go regarding this topic, and it will take more clinical trials to fully understand how cannabis helps with IBS.
Greencamp
FEBRUARY 2, 2019
Even though cannabis and cannabinoid-derived pharmaceuticals are both frequently used by HIV/AIDS patients, several studies show that something interesting happens when cannabis is consumed. But I haven’t seen any clinical trials looking at the direct effects of THC on the virus. What is HIV and how is it manifested?
Cannabis Law Report
OCTOBER 29, 2019
Wakshlag is well-known in the veterinary medicine community as the first doctor to conduct an efficacy study in dogs in a clinical trial at Cornell using ElleVet CBD/CBDA on dogs with multi-joint discomfort. The clinical trial results confirmed more than 80% of dogs showed significant or dramatic improvement.
The Cannigma
JANUARY 13, 2023
The authors noted that while “promising data are emerging on the possible role of ECS in migraine…proper placebo-controlled trials are needed to establish a therapeutic role for cannabinoids.” Chemovars classify cannabis based on the dominant cannabinoid, and there are three main types on the market right now.
Expert insights. Personalized for you.
72 
Let's personalize your content